Blog
RSS FeedPosted by Michael Wonder on 28 Oct 2018
Update on proposal to move to one funded brand of lamotrigine (Logem)
26 October 2018 - PHARMAC would like to thank everyone who provided feedback on a proposal to move to one ...
Posted by Michael Wonder on 28 Oct 2018
Calls for PHARMAC review after funds made available to offset wage settlements
24 October 2018 - A request that the government's drug-buying agency be reviewed has opposition support with claims money is ...
Posted by Michael Wonder on 28 Oct 2018
PBAC Public Summary Documents - July 2018 meeting
26 October 2018 - The Public Summary Documents (positive recommendations and subsequent decisions not to recommend) from the July 2018 PBAC ...
Posted by Michael Wonder on 28 Oct 2018
Potent drugs to treat lung cancer and high cholesterol added to PBS
28 October 2018 - Australians with advanced lung cancer and a genetic high-cholesterol condition will have cheaper access to potent ...
Posted by Michael Wonder on 26 Oct 2018
AbbVie’s CLL drug Venclyxto too expensive for NHS, says NICE
26 October 2018 - NICE has said AbbVie’s Venclyxto (venetoclax), in combination with development partner Roche’s MabThera/Rituxan (rituximab), is not ...
Posted by Michael Wonder on 25 Oct 2018
States threaten hospital funding war over $600m 'recalculation'
25 October 2018 - A dispute between the Commonwealth and the states and territories over health funding has reached critical ...
Posted by Michael Wonder on 25 Oct 2018
Price of medicinal cannabis halves, but still too expensive for many
26 October 2018 - The cost of medicinal cannabis has halved over the past year, but Australian patients are still ...
Posted by Michael Wonder on 25 Oct 2018
Review PHARMAC model, urge breast cancer petitioners
25 October 2018 - A group of women battling terminal cancer tell the Herald what they would do with extra time. ...
Posted by Michael Wonder on 24 Oct 2018
Systematic reviews of economic evaluations in health technology assessment: a review of characteristics and applied methods
22 October 2018 - When making decisions in health care, it is essential to consider economic evidence about an intervention. ...
Posted by Michael Wonder on 24 Oct 2018
MS and cholesterol drugs picked for new UK rapid uptake push
24 October 2018 - Accelerated Access Collaborative aims to break down barriers to faster uptake ...
Posted by Michael Wonder on 24 Oct 2018
Further update on proposal to fund glecaprevir with pibrentasvir (Maviret) for hepatitis C
24 October 2018 - This is a further update on the proposal to fund glecaprevir with pibrentasvir (Maviret) for hepatitis ...
Posted by Michael Wonder on 23 Oct 2018
$80 million investment in eye medication
24 October 2018 - The Australian Government will invest $80 million in eye medications through the Pharmaceutical Benefits Scheme, helping improve ...
Posted by Michael Wonder on 23 Oct 2018
Biosimilar adalimumab: a landmark for NHS medicines optimisation
23 October 2018 - The NHS’s bid to improve patient outcomes and save money by switching costly biological drugs for ...
Posted by Michael Wonder on 23 Oct 2018
$6.8 billion ‘high claim’ health cost sparks private insurer outcry
23 October 2018 - Australia’s private health funds paid $6.82 billion in “high claims” in one year, prompting renewed concerns ...
Posted by Michael Wonder on 23 Oct 2018
Eye disease drugs added to the PBS to benefit thousands of Australians
24 October 2018 - Thousands of Australians will have their vision saved or prolonged through increased access to eye medications. ...